evidence; may consider switching to an IL-12/23i biologic if the patient has contraindications to TNFi biologics, including congestive heart failure, previous serious infections, recurrent infections, or demyelinating disease, or prefers less frequent drug administration. 18. Switch to an IL-12/23i biologic over switching to an IL-17i biologic (PICO 60) Moderate ( 50 Strong recommendation supported by moderate-quality evidence showing IL-12/23i biologic is effective for IBD while an IL-17i biologic is not effective for IBD. * Active psoriatic arthritis (PsA) is defined as disease causing symptoms at an unacceptably bothersome level as reported by the patient, and judged by the examining clinician to be due to PsA based on ≥1 of the following: swollen joints, tender joints, dactylitis, enthesitis, axial disease, active skin and/or nail involvement, and extraarticular inflammatory manifestations such as uveitis or inflammatory bowel disease (IBD). † When there were no published studies,